---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-21-000059"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2021-12-13T23:59:59+00:00"
generated_at: "2026-06-28T01:34:30.758651+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Halozyme appoints Mark Snyder as General Counsel; Matsuda steps down Dec 31

## Summary
- Masaru Matsuda steps down as SVP, General Counsel, Chief Compliance Officer and Corporate Secretary effective Dec 31, 2021 to pursue another opportunity.
- Mark Snyder appointed to those roles effective Jan 3, 2022; previously SVP, Deputy General Counsel, Litigation at Qualcomm.
- Snyder brings nearly 30 years of legal experience, including IP, licensing, regulatory, antitrust, and litigation.
- Company expects to enter a separation agreement with Matsuda with benefits consistent with those disclosed in 2018 8-K.

## SEC filing metadata
- accession: 0001159036-21-000059
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2021-12-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903621000059/0001159036-21-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903621000059/halo-20211213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-21-000059
- JSON: https://secwatch.observer/filing/0001159036-21-000059.json
- Plain text: https://secwatch.observer/filing/0001159036-21-000059.txt

## Key facts
- Executive change
  Mark Snyder was appointed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at HALOZYME THERAPEUTICS, INC..
  - Action: will be appointed
  - Role: Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
  source text: Effective January 3, 2022, Mark Snyder will be appointed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903621000059/0001159036-21-000059-index.htm
- Executive change
  Masaru Matsuda departed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at HALOZYME THERAPEUTICS, INC..
  - Action: will step down
  - Role: Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
  source text: Masaru Matsuda will step down from his position as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company, effective December 31, 2021, to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903621000059/0001159036-21-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.